[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immuneering Corp Cl A (IMRX)

Immuneering Corp Cl A (IMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 348,070
  • Shares Outstanding, K 64,697
  • Annual Sales, $ 0 K
  • Annual Income, $ -56,020 K
  • EBIT $ -59 M
  • EBITDA $ -59 M
  • 60-Month Beta 0.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.53

Options Overview Details

View History
  • Implied Volatility 96.95% (-7.01%)
  • Historical Volatility 55.05%
  • IV Percentile 6%
  • IV Rank 2.33%
  • IV High 691.92% on 03/05/26
  • IV Low 82.73% on 03/23/26
  • Expected Move (DTE 1) 0.31 (6.12%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 191
  • Volume Avg (30-Day) 399
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 9,375
  • Open Int (30-Day) 8,906
  • Expected Range 4.83 to 5.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.30
  • Number of Estimates 2
  • High Estimate $-0.28
  • Low Estimate $-0.31
  • Prior Year $-0.42
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.03 +2.19%
on 05/12/26
6.22 -17.36%
on 04/27/26
-0.27 (-4.99%)
since 04/14/26
3-Month
4.67 +10.06%
on 03/19/26
6.22 -17.36%
on 04/27/26
+0.21 (+4.26%)
since 02/13/26
52-Week
1.24 +314.52%
on 05/15/25
10.08 -49.01%
on 09/22/25
+3.88 (+307.94%)
since 05/14/25

Most Recent Stories

More News
Can Immuneering's Pancreatic Cancer Survival Data Turn Market Skepticism Into Conviction?

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 8, 2026 Current Price $5.22 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Can Immuneering's Pancreatic Cancer...

IMRX : 5.14 (-4.46%)
Can Immuneering's Pancreatic Cancer Survival Data Turn Market Skepticism Into Conviction?

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 8, 2026 Current Price $5.22 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Can Immuneering's Pancreatic Cancer...

IMRX : 5.14 (-4.46%)
Can Immuneering's Pancreatic Cancer Survival Data Turn Market Skepticism Into Conviction?

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 8, 2026 Current Price $5.22 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Can Immuneering's Pancreatic Cancer...

IMRX : 5.14 (-4.46%)
Immuneering's Pancreatic Cancer Data Could Finally Answer Whether Survival Translates to Pivotal Trial Momentum

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 1, 2026 Current Price $5.38 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Immuneering's Pancreatic Cancer Data...

IMRX : 5.14 (-4.46%)
Immuneering's Pancreatic Cancer Data Could Finally Answer Whether Survival Translates to Pivotal Trial Momentum

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 1, 2026 Current Price $5.38 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Immuneering's Pancreatic Cancer Data...

IMRX : 5.14 (-4.46%)
Immuneering's Pancreatic Cancer Data Could Finally Answer Whether Survival Translates to Pivotal Trial Momentum

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 1, 2026 Current Price $5.38 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Immuneering's Pancreatic Cancer Data...

IMRX : 5.14 (-4.46%)
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO presentation...

IMRX : 5.14 (-4.46%)
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors...

IMRX : 5.14 (-4.46%)
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference

NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced...

IMRX : 5.14 (-4.46%)
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced...

IMRX : 5.14 (-4.46%)

Business Summary

Immuneering Corporation is a biopharmaceutical company advancing a pipeline of oncology and neuroscience product candidates. The company's product candidate includes IMM-1-104. Immuneering Corporation is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 5.76
2nd Resistance Point 5.57
1st Resistance Point 5.48
Last Price 5.14
1st Support Level 5.20
2nd Support Level 5.01
3rd Support Level 4.92

See More

52-Week High 10.08
Fibonacci 61.8% 6.70
Fibonacci 50% 5.66
Last Price 5.14
Fibonacci 38.2% 4.62
52-Week Low 1.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.